Abstract
Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.
Original language | English |
---|---|
Pages (from-to) | 1457-1460 |
Number of pages | 4 |
Journal | Japanese Journal of Clinical Ophthalmology |
Volume | 63 |
Issue number | 9 |
Publication status | Published - Sep 2009 |
ASJC Scopus subject areas
- Ophthalmology